Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 28, 2019

View Archived Issues

Forward genetics identifies new immune player

Reversible, selective, potent BTK inhibitors identified by Tethering-fragment-based screening

Immunogenicity and efficacy animal studies of a new vaccine against Lassa virus confirm protection

hIL-12 gene therapy can prolong survival in recurrent high-grade glioma patients

FDA clears IND for long-acting injectable antipsychotic based on MedinCell technology

Permanent chemotherapy-induced baldness modeled

Conditional deletion of Talpid3 produces mouse model of Joubert syndrome

Arvinas initiates first-in-human study of ARV-471

Spago Nanomedical initiates first clinical trial of SN-132D

2-75, a novel enzalutamide-HDAC inhibitor hybrid with efficacy in models of prostate cancer

Adaptimmune, Noile-Immune announce collaboration to develop next-generation SPEAR T-cell products

New selective and potent class I HDAC inhibitor from Merck activates HIV latency ex vivo

Japan Tobacco discloses pyruvate dehydrogenase kinase inhibitors

Asahikawa Medical University, Hokkaido University patent echinomycin derivatives

Lilly discovers TRPA1 antagonists

New polycomb protein EED inhibitors identified at Mirati Therapeutics

Boehringer Ingelheim describes new ghrelin O-acyltransferase inhibitors

Bristol-Myers Squibb presents discovery of lupus candidate BMS-615

IRLAB to prioritize L-dopa-induced dyskinesia indication in development of IRL-790

Kintai Therapeutics announces academic collaborations in cancer

Genisphere collaborates with University Hospitals in pancreatic cancer

FDA approves Nourianz for Parkinson's disease

European Commission approves Soliris for neuromyelitis optica spectrum disorder

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 28, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Grace Therapeutics hits CRL setback with GTx-104 despite positive trial
BioWorld
Grace Therapeutics Inc.’s hopes of becoming the first company in decades to update the standard of care in aneurysmal subarachnoid hemorrhage were delayed after...
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...